SPRC · SciSparc Ltd. Ordinary Shares
View on chartInsiders & Stakes
| Shrem Itschak Director | ▼ Sell | Open Market | 10,596 Shares held | 6/1/2026 | View profile |
Transaction History
| Shrem Itschak | ▼ Sell | Open Market | 462 | $5K | 6/1/2026 |
| Shrem Itschak Director | ▼ Sell | Open Market | 10,596 Shares held | 6/1/2026 | View profile |
| Shrem Itschak | ▼ Sell | Open Market | 462 | $5K | 6/1/2026 |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
SciSparc Subsidiary Reports Quantum Gene Analysis of Billions
SciSparc’s subsidiary NeuroThera Labs announced that its CliniQuantum platform successfully analyzed billions of gene combinations using real‑world clinical data on a quantum architecture owned by an S&P 500 company. The achievement shows the company’s ability to use quantum computing for big genetic analysis, a key area for drug discovery. The news comes as shares trade near $6.46, close to a support level tested 15 times, with an RSI of 40.6.
SciSparc Subsidiary Reports Quantum Gene Analysis of Billions. SciSparc’s subsidiary NeuroThera Labs announced that its CliniQuantum platform successfully analyzed billions of gene combinations using real‑world clinical data on a quantum architecture owned by an S&P 500 company. The achievement shows the company’s ability to use quantum computing for big genetic analysis, a key area for drug discovery. The news comes as shares trade near $6.46, close to a support level tested 15 times, with an RSI of 40.6.